A B S T R A C T When thrombin is added to washed human platelets, one of its actions results in activation of a phospholipase that hydrolyzes arachidonic acid from phospholipids. The arachidonate is converted to the cyclic endoperoxides (prostaglandin G2 and prostaglandin H2) by fatty acid cyclo-oxygenase. These compounds are then converted to thromboxane A2, also called rabbit aorta-contracting substance, by thromboxane synthetase. These labile, pharmacologically active compounds then break down to inactive products including thromboxane B2 and malonaldehyde. Incubation of platelets with either dibutyryl cyclic adenosine 3',5'-monophosphate (dBcAMP) or prostaglandin E, (PGE,) before thrombin addition blocks the subsequent formation of oxygenated products of arachidonic acid including thromboxane A2, thromboxane B2, and malonaldehyde. In contrast, when arachidonic acid is added directly to platelets, prior incubation with dBcAMP or PGE, does not inhibit production of the prostaglandins or their metabolites. Thrombin treatment of platelets also blocks the acetylation of cyclo-oxygenase by aspirin since the hydrolyzed arachidonic acid competes with aspirin for the active site on cyclo-oxygenase. Prior treatment of platelets with dBcAMP or PGE, reverses the thrombin inhibition of the acetylation of cyclo-oxygenase. We conclude that agents which elevate platelet cAMP levels inhibit the hydrolysis of arachidonic acid from platelet phospholipids. We also find that prostaglandin synthesis can be dissociated, in part, from platelet aggregation and release, and that cAMP has separate actions on these processes. Higher thrombin concentrations are required to stimu-
INTRODUCTION
Recently, it has been postulated that the platelet release reaction induced by thrombin and other agents may be mediated by prostaglandins (1) (2) (3) (4) (5) (6) . When thrombin or collagen are added to intact platelets, arachidonic acid is rapidly hydrolyzed from platelet phospholipids (7, 8) and metabolized to cyclic endoperoxide compounds by a particulate enzyme fatty acid cyclo-oxygenase. Subsequently, the cyclic endoperoxides prostaglandin G2 (PGG2)1 and prostaglandin H2 (PGH2) are converted to thromboxane A2 (TA2) which is broken down to nonprostanoate metabolites including malonaldehyde and thromboxane B2 (TB2). Both cyclic endoperoxides and TA2, the latter being much more potent, induce platelet aggregation and release (5) .
Aspirin inhibits platelet function by preventing formation of cyclic endoperoxides (9) . Aspirin inactivates platelet cyclo-oxygenase, and we have recently shown that aspirin acetylates the enzyme's active site (10, 11) . Because of the lability of RCS (TA2) in aqueouis media at 37°C, all samples were assayed at 30 s after the addition of arachidonate, PGH2, or thrombin.
Arachidonic acid, the cyclo-oxygenase substrate, inhibits the aspirin-mediated acetylation by competing with the drug for the active site of the enzyme. Agents which elevate platelet cyclic adenosine 3',5'-imonophosphate (cAMP) levels (e.g. dibultyrl (dB)cAMP or PGE,) inhibit subsequent platelet release and aggregation indtuced by thrombin and a variety of aggregating agents (9, (12) (13) (14) (15) (16) . Whether or not these aggregating agents depress the basal platelet cAMP level as the cause of platelet release and aggregation has been the subject of much controversy (9, (12) (13) (14) (15) . Increasing the platelet cAMP level has been reported to inhibit the activity of cyclo-oxygenase (16) . This concltusion was based on restults of experiments where platelets were incubated with dBcAMP before addition of collagen or arachidonate. This treatment restulted in a redtuction in the formation of TB2.
In contrast to this report we find that dBeAMP or PGE, appear to inhibit the hydrolysis of arachidonic acid from platelet phospholipids which occurs after thrombin addition to platelets. We find no evidence that high levels of cAMP affect platelet cyclooxygenase or thromboxane synthetase.
METHODS
Experiments were performed with washed human platelets prepared by modification of a previously described method (2) . Fresh blood was withdrawn from healthy donors who had not taken any medication (including aspirin) for at least 2 wk before collection time. Blood withdrawn was collected directly into 7.5% (vol/vol) 77 mM EDTA and centrifuged in plastic tubes at 150 g for 10 min. The plateletrich plasma was centrifuged at 1,800g for 6 min and the platelet pellet was resuspended in 0. Materials. Arachidonate was purchased from NuCheck Prep, Elysian, Minn. PGH2 was prepared and puirified as previously described (5). [1-_4C]Arachidonate was puirchased from Amersham/Searle Corp., Arlington Heights, Ill., and [14C]serotonin binoxalate was pturchased from New England Nuclear, Boston, Mass. PGE, was kindly supplied by Dr. J. Pike, The Upjohn Co., Kalamazoo, Mich. N6'-02'-dB cAMP-monophosphate was purchased from Sigma Chemical Co., St. Louiis, Mo. Huiman a-thrombin was pturified and assayed as previouisly described (20) .
RESULTS
Effect of dBcAMP on formationr of TA2. The addition of increasing concentrations of arachidonate, PGH2 or thrombin to platelet suspensions prodtuced a dose-dependent increase in rabbit aorta-contracting substance (TA2, Fig. 1 ). When the platelets were incubated with 2 mM dBcAMP before addition of arachidonate or PGH2, there was no change in the production of the rabbit aorta-contracting substances (RCS). However, RCS formation induced by thrombin was markedly inhibited by dBcAMP (Fig. 1) . The effect ofvarying the concentration ofdBcAMP is shown in Fig. 2 2 The effect of dBcAMP concentration on the generation of RCS induiced by arachidonate and thrombin.
The experiment was performed as in Fig. 1. after arachidonic acid. The same results were obtained uisiing PGE1 (3 1AIv) where platelet cAMP levels were elevated 15-fold above base-line levels (data not shown).
When prostaglandin synthesis was measured by determining the formation of [14C]TB2 from [1-14C]-arachidonate, similar results were obtained as shown in Fig. 3 . Thus, incubation of platelets with 2 mM dBcAMP did not reduce the generation of TB2. In other experiments using [1-_4C]arachidonate at concentrations from 0.25 to 15 ,ug/ml (1-50 ,uM) and dBcAMP concentrations from 0.5 to 5 mM, similar results were obtained, i.e., dBcAMP did not affect the production of TB2 from arachidonate.
Effect of dBcAMP on formation of MDA. MDA is a product of arachidonate metabolism which may arise both from breakdown of cyclic endoperoxides and TA2 (Fig. 4) . The effect of increasing thrombin concentration on MDA production is shown in Fig. 5 . The formation of MDA is dependent on several enzymes (Fig. 4) but the limiting step is arachidonate hydrolysis from phospholipids. This was demonstrated by measuring the inhibition of cyclo-oxygenase acetylation after thrombin addition (Fig. 5) . It has been shown previously that aspirin acetylates the active site of cyclo-oxygenase and that the acetylation is competitively inhibited by the substrate arachidonate (11) . The inhibition by arachidonate correlates with its activity as a cyclo-oxygenase substrate (i.e., Km as stubstrate = Ki as inhibitor). Furthermore, other unsaturated fatty acids are less effective as inhibitors of acetylation in parallel with their function as cyclooxygenase substrates (i.e., better substrates are better inhibitors [ 1] ). We suggest that the degree of inhibition of aspirin acetylation of cyclo-oxygenase after thrombin treatment is a function of the arachidonate concentration presented to the enzyme. As shown in Fig. 5 , the inhibition of acetylation by thrombin parallels malonaldehyde production. That the inhibition of acetylation is due to arachidonic acid is suggested by the finding that when aspirin was added 5 min after throimbin, no inhibition of acetylation was observed (data not shown). The arachidonate hydrolyzed after thrombin is all metabolized in 5 min. Assuming that inhibition of acetylation of cyclo-oxygenase can be used to measure arachidonic acid A. hydrolysis, we tested the effect of dBcAMP on the inhibition of acetylation of cyclo-oxygenase by thrombin. As shown in Table I , dBcAMP treatment of platelets alone had no effect on cyclo-oxygenase acetylation whereas the inhibition of acetylation by (Fig. 6) . Dissociation of prostaglandin synthesis from platelet aggregation and release. Our experiments suggest that elevation ofplatelet cAMP levels blocks the arachidonate hydrolysis that follows thrombin addition without significantly affecting cyclo-oxygenase or thromboxane synthetase. There are other sites of cAMP action in platelets as shown in Figs. 7 and 8 . Thus, platelet aggregation and ADP release induced by arachidonate, PGH2, or thrombin were inhibited by prior treatment with dBcAMP even though there was no inhibition of prostaglandin syntheseis from either arachidonate or PGH2 as measured by RCS, TB2 (data for PGH2 not shown), or MDA formation. These results suggest that platelet aggregation and release are blocked by dBcAMP by a mechanism which is independent of its effects on arachidonate metabolism. The dissociation between prostaglandin synthesis and serotonin release is shown in Fig. 5 where the concentration of thrombin required to stimulate prostaglandin synthesis (0.05-2 U/ml) is greater than that required for serotonin release (0.02-0.1 U/ml).
DISCUSSION
Previous investigations have suggested that plateletaggregating agents stimulate prostaglandin synthesis Suspensions of platelets were incubated at 37°C for 15 min either alone or with dBcAMP. [acetyl-3H]Aspirin was added to a final concentration of 10 ,uM and the incubation was continued for an additional 5 min. Thrombin, ifpresent, was added 15 s after the aspirin. At the end of the incubation, samples were boiled in sodium dodecyl sulfate, electrophoresed, and radioactivity in cyclo-oxygenase assessed (10, 11 FIGURE 6 Arachidonate-, PGH2-, and thrombin-induced generation of MDA. Platelet suspensions were incubated 3 min with the indicated concentrations of arachidonate, PGH2, or thrombin with or without prior incubation with 1 mM dBcAMP as in Fig. 1 , and then assayed for MDA as described in Methods.
in platelets by activating a phospholipase which hydrolyzes arachidonic acid from platelet phospholipids (1, 3, 7, 8) . When platelets lipids were labeled with radioactive arachidonic acid and the platelets then treated with thrombin, free arachidonic acid appeared with subsequent formation of prostaglandins, endoperoxides, and thromboxanes (7, 8 7 Platelet aggregation. Aggregation of human platelet suspensions by arachidonate (400 ng/ml), PGH2 (500 ng/ml), and thrombin (150 mU/ml). dBcAMP (1 mM) was preincubated with platelet suspensions as described in Fig. 1 . mation of TB2 from arachidonic acid. These authors incubated intact platelets with ['4C larachidonate in the presence and absence of dBeAMP, and after acidether extraction of the platelets, determined TB2 formation by thin-layer chromatography. We hav e measured TB2 in the same manner that they did at widely varying concentrations of both arachidonic acid and dBcAMP and find no inhibition. There is an additional unexplained difference between our results. Malmsten found that dBcAMP inhibited arachidonate but not PGH2-induced platelet aggregation whereas we find that aggregation is inhibited in both cases without evident effect on prostaglandin synthesis. We are unable to explain the reason for the differences in experimental results. We conclude that dBcANIP has no direct inhibitory effect on cyclo-oxygenase.
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[ARACHIDONATE] ng/ml [PGH2] ng/ml [THROMBIN] mUl/ml FIGURE 8 Arachidonate-, PGH2-, and thrombin-induced ADP release. ADP released during aggregation of platelet suspensions was assayed as described in Methods by removing a 20-gl sample of the reaction mixture 3 min after the addition of the aggregating agent. 1 mM dBcAM1P was preincubated with platelet suspensions as described in Fig. 1 .
vivo remains to be elucidated. That prostaglandin metabolites may not be obligate intermediates in the release reaction induced by thrombin is suggested by several lines of evidence. As shown in Fig. 5 , the concentration of thrombin required to induce serotonin release from platelets is significantly less than that required to stimulate arachidonic acid hydrolysis. Further, aspirin-treated platelets or platelets from donors who have ingested aspirin respond normally to thrombin in vitro (22) (23) (24) . Even using collagen, where aspirin treatment does inhibit the release reaction, higher concentrations' of collagen overcome aspirin inhibition (23) . However, prostaglandins are important in vivo since aspirin induces a mild hemostatic defect in normal individuals, and in patients with defects in intrinsic coagulation, a much more severe defect is produced (25) . If not essential for aggregation and release, prostaglandins may serve as modifiers of platelet function, the effects of which could be important in pathological states such as myocardial infarction (26) .
